Genmab A/S (GMAB) एक सार्वजनिक रूप से कारोबार करने वाली कंपनी है में स्वास्थ्य सेवा क्षेत्र, संचालन करती है Biotechnology उद्योग. कंपनी का मुख्यालय है Copenhagen, Denmark. वर्तमान CEO हैं Jan van de Winkel.
GMAB के पास है IPO तिथि 2009-06-01, 2,638 पूर्णकालिक कर्मचारी, पर सूचीबद्ध NASDAQ Global Select, बाजार पूंजीकरण $17.94B.
Genmab A/S is a Danish biopharmaceutical company founded in 1999 that develops antibody-based therapeutics for cancer and other serious diseases. The company's commercial portfolio includes DARZALEX (daratumumab) for multiple myeloma and other blood cancers, teprotumumab for thyroid eye disease, ofatumomab for chronic lymphocytic leukemia and multiple sclerosis, and amivantamab for gastric, esophageal, and lung cancers. Genmab maintains a robust pipeline of clinical and pre-clinical programs, including tisotumab vedotin for solid tumors, epcoritamab for lymphomas, and multiple early-stage candidates in Phase 2 development across oncology and other therapeutic areas. The company partners with leading pharmaceutical and biotech firms including Seagen, AbbVie, Janssen, BioNTech, and Novo Nordisk to advance its research and development efforts globally.
